What an Expiry Date Really Proves: Inside ICH Q1 Stability Testing

The short version#

The expiry date on a medicine is the last day the manufacturer has evidence that the product still meets its approved limits for identity, strength, quality, and purity, assuming you stored it the way the label says. That printed line is the visible tip of months or years of laboratory testing, and the rules governing that testing are being redrawn. In 2025 the International Council for Harmonisation (ICH) opened a draft guideline, ICH Q1, for public consultation. It merges a scattered family of stability documents into one framework.

Key points#

• An expiry date certifies proven quality up to that day under labeled storage; it is not a prediction of sudden failure the day after.
• Two study designs do the work: real-time storage sets the shelf life, and accelerated stress testing supports and stresses it.
• The draft ICH Q1 pulls the older Q1A through Q1F documents and the biologics guideline Q5C into a single, risk-based text.
• New emphasis falls on predictive modeling, prior knowledge, and in-use stability after a container is first opened.
• Storage conditions are part of the promise: heat and humidity can shorten real shelf life well before the printed date.

Reading the date on the box#

Think of the expiry date as a warranty backed by data rather than a spoilage alarm. It states that, up to that day, a batch has been shown to hold its label claims when kept as instructed. Two conditions are baked into that statement, and both matter to patients.

First, the promise is conditional on storage. A tablet you keep in a hot glovebox or a steamy bathroom cabinet lives under conditions the testing never certified, so it may drift out of specification earlier than the date printed on it suggests. Second, the date marks the edge of demonstrated evidence, not a cliff where a safe drug becomes a dangerous one overnight. For most products a small margin past the date is a loss of assurance rather than proof of harm. For medicines where potency is critical, such as certain injectables or emergency drugs, that boundary deserves real respect because a modest loss of strength can carry outsized consequences.

How stability is actually proven#

Stability testing turns a plain question into a controlled experiment: how does a medicine's quality change over time under defined heat, humidity, and light? Samples sit in tightly regulated chambers and are pulled at set intervals to check whether the active ingredient remains present at full strength, whether breakdown products are accumulating, and whether the physical form still dissolves and performs as intended.

Two study types anchor the effort.

Real-time (long-term) testing stores the product under conditions meant to mirror ordinary storage and runs for the full intended shelf life. Under the long-standing ICH parameters, that means at least twelve months at 25 degrees Celsius and 60 percent relative humidity, or an alternative of 30 degrees and 65 percent, with testing carried out to the entire claimed duration.

Accelerated testing does the opposite: it deliberately stresses the product, classically at least six months at 40 degrees Celsius and 75 percent relative humidity, to hurry chemical change and surface weaknesses early. If accelerated samples cross a pre-defined "significant change" limit, that result triggers testing at an intermediate condition and closer analysis before any shelf life can be claimed.

The division of labor is clean. Real-time data ultimately fixes the expiry date. Accelerated data supports it, permits limited and carefully justified early extrapolation, and flags formulations that will not survive a long shipment or a hot warehouse.

Why many guidelines became one#

For more than two decades, stability rules lived across a shelf of separate documents. The original ICH Q1A, revised to Q1A(R2) and still hosted by the U.S. Food and Drug Administration, set the core expectations for new drug substances and products. Companion texts handled photostability, new dosage forms, bracketing and matrixing study designs, the definition of climatic zones, and how to evaluate the resulting data. A separate guideline, Q5C, covered biological products, which age by different chemistry than small molecules.

The draft ICH Q1 gathers that whole family, the Q1A through Q1F series plus Q5C, into one document. According to the European Medicines Agency, which posts the draft for comment, the revision organizes stability expectations for both drug substances and drug products under shared, science- and risk-based principles. The goal is coherence: one place to look, one vocabulary, and one logic that spans conventional tablets, biologics, and newer therapy types instead of several overlapping texts written in different eras.

What the draft modernizes#

The consolidated draft keeps the tested foundation and updates the reasoning around it. Three themes stand out.

Modeling and prior knowledge#

The draft gives a clearer home to predictive stability modeling and to prior knowledge, so established understanding of a molecule or a manufacturing platform can inform, without replacing, the required data. Statistical methods for reading trends and estimating shelf life are treated more explicitly. Used honestly, modeling trims redundant testing; used loosely, it can overreach, which is why the draft frames these tools as justified additions to evidence rather than substitutes for it.

In-use stability#

Many medicines are not finished the moment they are opened. A reconstituted antibiotic, a multi-dose eye drop, or an opened injectable pen starts a second clock once its seal is broken. In-use stability testing defines how long a product stays acceptable after first opening or reconstitution. That is the science behind the "use within 28 days of opening" line you have read on a carton and probably obeyed without asking where the number came from.

Leaner study design#

The framework continues to support bracketing and matrixing, statistically defensible designs that test a reasoned subset of samples, such as the extreme strengths or the largest and smallest container sizes, rather than every possible combination. Done properly, this reduces testing burden without weakening the conclusion.

Why a single standard helps everyone#

A harmonized guideline matters beyond any one laboratory. When regulators in different regions accept the same stability standard, one body of evidence can support approval across multiple markets. That cuts duplicated testing and supports steadier global supply of the medicines people rely on.

One caveat keeps this honest. ICH Q1 is still a draft. At the second stage of the ICH process it is published for comment, not finalized, and its specifics can change before adoption and regional implementation. What is durable is the principle it formalizes: an expiry date is the visible endpoint of a hidden, rigorous chain of evidence.